Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?

Clinica Terapeutica

Volumn 160, Issue 2, 2009, Pages 121-123

  Luzi, G ^a   Lagana B ^a   Salemi, S ^a   Di Rosa, R ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti TNFc ; Etanercept; Glucocorticoids; Infections; Rheumatoid arthritis

Indexed keywords

ETANERCEPT; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; MALE; MIXED INFECTION; OTITIS; PNEUMONIA; RHEUMATOID ARTHRITIS; RISK FACTOR; STUDENT T TEST; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; CANDIDIASIS, VULVOVAGINAL; DISEASE SUSCEPTIBILITY; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; OTITIS MEDIA; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATORY TRACT INFECTIONS; URINARY TRACT INFECTIONS;

EID: 66249083466     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Maini R, St Clair EW, Breedveld F, et al. and the ATTRACT Study Group. Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354:1932-9
2. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130:478-86
3. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biological agents. Arthritis and Rheum 2005; 52:3403-12
4. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287-93
5. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30:2563-71
6. Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis J Rheumatol 2005; 32:1232-42
7. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004; 16:393-8
8. Inanc N, Direskeneli H. Serious infections under treatment with TNFα antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int 2006; 27:67-71
9. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor a therapy. Arthritis Rheum 2003; 11:3013-22
10. ArnettFC, Edworhty SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24
11. Moiton MP, Richez C, Dumoulin C, et al. Role of anti-tumor necrosis factor-a therapeutic agents in the emergence of infections Clin Microbiol Infect 2006; 12:1151-53
12. Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006; 33:854-61
13. Bijlsma JW, Boers M, Saag KG, et al. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003; 62:1033-37
14. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96:115-23
15. Forster A, Gasser LH, Daneel S, et al. Serious infections and their predictors in a Swiss cohort of rheumatoid arthritis patients treated with TNF inhibitors. Arthritis Rheum 2003; 48 (s):328
16. Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases. Arthritis Rheum 2004; 50:3408-17
17. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and risk of hospitalization for pneumonia. Arthritis Rheum 2006; 54:628-34
18. Trikudanathan S, McMahon GT. Optimum management of glucocorticoid-treated patients. Nat Clin Pract Endocrinology Metabolism 2008; 5:262-71